Antibiotice

Name

Antibiotice

Legal name

S.C. ANTIBIOTICE S.A.

Website

https://antibiotice.ro

Company type

Public

Founded year

1955

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Antibiotice is a Romanian pharmaceutical manufacturer founded in 1955, producing over 165 generic medicines across 8 GMP-certified production flows, with FDA approvals enabling US exports, and serving hospitals, pharmacies, and public health systems in 70+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceutical manufacturing
• Prescription human medicines
• Veterinary pharmaceutical products
• Active pharmaceutical ingredients
• Contract manufacturing services

Headquarters

HQ city

Valea Lupului

HQ country

Romania

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Antibiotice manufactures and sells generic medicines including prescription (RX) and over-the-counter (OTC) products. Portfolio includes over 165 medicines covering therapeutic areas such as anti-infectives, cardiovascular, oncology, central nervous system, and quality of life prophylaxis. Products are sold domestically in Romania and exported to 70+ countries worldwide through direct sales, distributors, and international tenders.
2. Veterinary Products: Production and sale of veterinary medicinal products including prescription veterinary products and the VetAria+ product line.
3. Active Pharmaceutical Ingredients: Manufacture and supply of active pharmaceutical ingredients including Nystatin, which is supplied to international partners.
4. Contract Manufacturing: The company offers contract manufacturing services for pharmaceutical products under GMP conditions.
5. Cosmetics and Medical Devices: Production and sale of cosmetic products and medical devices as part of diversified product portfolio.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Antibiotice manufactures and distributes a broad portfolio of generic pharmaceutical products, including human prescription (RX) and over-the-counter (OTC) medicines, veterinary products, active pharmaceutical ingredients, nutritional supplements, cosmetics, medical devices, biocides, and microbial biostimulators. The company operates 8 GMP-certified production flows at its Iași industrial platform and exports to over 70 countries. It also offers contract manufacturing services under GMP conditions for third-party pharmaceutical products.

Product overview

Antibiotice is a Romanian pharmaceutical company that manufactures and distributes a broad portfolio of generic medicines. The company operates eight GMP-certified production flows and produces human medicines (prescription and OTC), veterinary products (VetAria+), nutritional supplements (Nutriensa), active pharmaceutical ingredients, cosmetic products, medical devices, biocides, and microbial biostimulators. The portfolio covers therapeutic areas including anti-infectives, cardiovascular, oncology, and central nervous system medications. The company also offers contract manufacturing services and exports to over 70 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• VetAria+: Veterinary product line brand
• Nutriensa
• Zifelle
• a+ Oxy
• a+ Complex Solution

Products and services

• Prescription Human Medicines (RX) Prescription pharmaceutical products for human use covering therapeutic areas including anti-infectives, cardiovascular, oncology, and central nervous system; supplied to hospitals, pharmacies, and government health systems domestically and internationally.
• Over-the-Counter Medicines (OTC)

Quantifiable outcome

• Over 165 medicines in portfolio covering multiple therapeutic areas
• +6 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, strategic and minor.

• United Nations Global Compact (UNGC)coreStrategic or Co-development Partner · 1 June 2025In June 2025, Antibiotice became a member of the UN Global Compact, the world's largest corporate sustainability initiative. Through this affiliation, the company commits to upholding the Ten Principles of the UNGC on human rights, labor standards, environmental protection, and anti-corruption, and aligns operations with the 17 UN Sustainable Development Goals.
• Science Based Targets initiative (SBTi)coreStrategic or Co-development Partner · 1 January 2025In 2025, Antibiotice joined SBTi, committing to set carbon reduction targets aligned with the 1.5°C global warming pathway. Once officially validated by SBTi, the company will publish its decarbonization objectives and plans, ensuring transparency and accountability.
• Romanian Sustainability CoalitionstrategicStrategic or Co-development Partner · 1 January 2023Since 2023, Antibiotice has been a member of the Romanian Sustainability Coalition supported by the Embassy of Sustainability and the Department for Sustainable Development within the Government of Romania. Through this partnership, the company supports Sustainable Development Goals focused on health and well-being, clean energy, and climate action. The Coalition brings together 173 organizations.
• Alexandru Ioan Cuza University IașistrategicStrategic or Co-development PartnerTraditional collaboration partnership with the Faculty of Chemistry and Faculty of Biology for student recruitment, internships, and talent development in pharmaceutical sciences.
• Grigore T. Popa University of Medicine and Pharmacy IașistrategicStrategic or Co-development PartnerPartnership with Faculty of Pharmacy and Bioengineering for talent recruitment, internships, and joint master's programs. In 2024, launched new master's programs in Pharmaceutical Safety Assessment and Regulatory Affairs.
• Gheorghe Asachi Technical University IașistrategicStrategic or Co-development PartnerPartnership with Faculty of Chemical Engineering and Environmental Protection for student recruitment and practical training in pharmaceutical manufacturing.
• Regional Center for Blood Transfusion IașiminorStrategic or Co-development PartnerPartnership for organizing biannual mobile blood donation campaigns. Antibiotice employees have participated since 2010 in blood donation campaigns organized in partnership with the center.
• Petru Poni Technological High SchoolminorStrategic or Co-development PartnerPartnership for vocational training and dual education programs in the pharmaceutical field.
• Carol I High School IașiminorStrategic or Co-development PartnerEducational partnership for student engagement and career orientation in pharmaceutical industry.
• EcoVadisstrategicOthersThird-party sustainability assessment provider. Antibiotice achieved Gold Medal (Top 5%, 98th percentile globally) in 2026 EcoVadis assessment with a score of 85/100.
• SustainalyticsstrategicOthersESG assessment provider collaborating with Bucharest Stock Exchange. Antibiotice has participated in ESG assessment program since 2021.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Zentiva: Pan-European generic pharmaceutical manufacturer headquartered in Prague with broad portfolio across therapeutic areas and 30+ country footprint. Closely comparable to Antibiotice as a mid-sized European generic manufacturer with EU tender exposure and Eastern European production base.
• Krka: Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished-dose production, exporting to 70+ countries. Highly comparable to Antibiotice in scale, geographic model, and portfolio breadth across prescription generics, veterinary, and consumer health.
• Gedeon Richter: Hungarian pharmaceutical company with strong generic and specialty pharma portfolio across Central/Eastern Europe and international markets. Comparable as a regional Central/Eastern European pharma manufacturer with EU regulatory footprint and similar institutional customer base.
• Polpharma: Polish pharmaceutical manufacturer producing generics, APIs, and OTC products across Eastern and Central Europe. Directly comparable in therapeutic areas, manufacturing model, and Eastern European institutional customer base.
• Alvogen: US-headquartered generic pharmaceutical company with strong Central/Eastern European manufacturing presence and emerging-market focus. Comparable as a mid-sized generic manufacturer with international tender exposure and similar geographic profile to Antibiotice.

Broad incumbents

• Stada Arzneimittel: Large German-headquartered European generic pharmaceutical and consumer healthcare company with extensive EU tender footprint. Comparable in product categories (generics, OTC, specialty) and institutional customer mix, though larger and more diversified geographically.
• Hikma Pharmaceuticals: UK-headquartered multinational pharmaceutical company with strong generics, injectables, and branded portfolio across MENA, Europe, and the US. Comparable through injectable generics manufacturing, FDA-approved operations, and public tender expertise similar to Antibiotice.
• Sandoz: Global generic and biosimilar pharmaceutical company spun off from Novartis, with broad EU and US generic portfolio. Comparable as an FDA-approved sterile injectable manufacturer and EU tender supplier, though substantially larger and more global than Antibiotice.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive portfolio across all major therapeutic areas and global EU/US tender participation. Comparable in core generic manufacturing and FDA-approved operations, though vastly larger and more diversified.
• Viatris: Global healthcare company formed via Mylan-Upjohn merger, with strong generic, biosimilar, and branded portfolio across 165+ countries. Comparable geographic breadth (Antibiotice reaches 70+ countries), generic injectables, and FDA-approved manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=cXsYj-NkPWg
• Facebookfacebook.com/AntibioticeIasi
• LinkedInlinkedin.com/company/antibiotice

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antibiotice